Do plasma emicizumab levels correlate with risk of bleeding?¶
Answer: No. In this real-world evidence (RWE) prospective study, there was no correlation.
Steady-state plasma emicizumab concentration did not correlate with total or spontaneous annualized treated bleed rate and annualized joint bleed rate or with patient age at enrolment, body weight, or body mass index. Dose capping at 150 mg/wk did not result in lower emicizumab concentrations in the 9 patients with body weight >100 kg.
— study abstract
- The authors call for reconsidering the minimum effective drug concentration, given the lack of correlation.
- In fact, in this study from a resource-limited setting, low-dose emicizumab was effective in preventing bleeding and improving QOL. ABR was comparable to full dose, from this very limited data set.
Source: Plasma emicizumab concentrations and bleeding rates in children and adults with severe hemophilia A